Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,420
Out of 5,123 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $20.03 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $64.64 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $766.63 | +10.87% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $2.06 | +773.79% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.91 | +6,489.06% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $1.97 | +356.85% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.28 | +441.40% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $185.36 | +76.41% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $57.68 | +884.74% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $458.81 | -38.75% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.38 | +479.71% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.05 | +9,233.33% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $367.80 | -19.79% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $149.37 | -42.42% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $27.76 | +72.91% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.31 | +464.97% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $26.57 | +170.98% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.72 | +191.55% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $102.76 | -2.69% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $217.38 | -7.54% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $72.36 | +17.47% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $14.26 | +124.40% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $17.03 | +1,174.22% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $47.90 | +0.21% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $16.08 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $331.24 | -53.51% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $57.15 | +102.97% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.79 | +1,461.12% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $11.09 | +152.48% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $213.56 | -61.60% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $478.93 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.96 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.03
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.64
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $766.63
Upside: +10.87%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $2.06
Upside: +773.79%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.91
Upside: +6,489.06%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $1.97
Upside: +356.85%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.28
Upside: +441.40%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $185.36
Upside: +76.41%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $57.68
Upside: +884.74%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $458.81
Upside: -38.75%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.38
Upside: +479.71%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.05
Upside: +9,233.33%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $367.80
Upside: -19.79%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $149.37
Upside: -42.42%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $27.76
Upside: +72.91%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $5.31
Upside: +464.97%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $26.57
Upside: +170.98%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.72
Upside: +191.55%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $102.76
Upside: -2.69%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $217.38
Upside: -7.54%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $72.36
Upside: +17.47%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $14.26
Upside: +124.40%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $17.03
Upside: +1,174.22%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $47.90
Upside: +0.21%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $16.08
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $331.24
Upside: -53.51%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $57.15
Upside: +102.97%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.79
Upside: +1,461.12%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $11.09
Upside: +152.48%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $213.56
Upside: -61.60%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $478.93
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.96
Upside: -